Linked Life Data

14584952

Source:http://linkedlifedata.com/resource/pubmed/id/14584952

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2003-10-30
pubmed:abstractText
The facile reaction of vancomycin with various PEG linkers, at the V(3) position, has been selectively accomplished by using an excess of base in DMF. Using rPEG as a blocking group for V(3) provides crystalline derivatives that can be further PEGylated to give pure V(3)-X(1) latentiated species (transport forms). V(3) tetrameric species were also prepared in order to increase the loading of drug on PEG. All PEG-vancomycin transport forms show significant antibacterial activity that is on the same order of native vancomycin. Significant increases in the AUC were observed for all PEG-vancomycin conjugates thus making them potential single dose therapies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5021-30
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Poly(ethylene glycol) transport forms of vancomycin: a long-lived continuous release delivery system.
pubmed:affiliation
Enzon Pharmaceuticals Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854, USA. richard.greenwald@enzon.com
pubmed:publicationType
Journal Article